L&T Technology Services Unveils CoE to Offer Suite of Automotive Solutions on AWS
9.3.2023 10:30:00 EET | Business Wire | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global pure-play engineering services company, today announced a new Centre of Excellence (CoE) in Mysore (Karnataka, India) that leverages the power of the cloud with Amazon Web Services (AWS). The CoE will allow LTTS to transition its suite of cutting-edge technologies focused on the future of mobility and reduce time-to-market for end customers. By leveraging AWS infrastructure, LTTS will provide an opportunity to use AWS to support the automotive domain.
With its rich engineering domain expertise in Electric, Autonomous, and Connected Vehicles (EACV), LTTS has been helping OEMs to develop next-generation Vehicles and Aircraft that have tailored solutions focused on safety and security. The new CoE will leverage LTTS' cross-disciplinary skillsets covering embedded, mechanical, and digital facets of engineering.
LTTS has been actively working with global technology leaders like AWS to bring digital engineering solutions to end customers on the cloud. AnnotAI , Connected Cars , and SafeX are some of the LTTS solutions that will be deployed in AWS Marketplace to optimize R&D innovation on the cloud to create enterprise-leading technology solutions.
LTTS’ industry leading mobility solutions are helping OEMs to build innovative next-generation vehicles to meet and exceed the standards for transport safety, security, and emission regulations. LTTS’ AnnotAI, Connected Cars and SafeX solutions have already been deployed for leading global Automotive OEMs and Tier-1 customers, helping them reap significant faster time-to-market benefits. As part of the CoE, AWS software-defined vehicle and AWS IoT FleetWise will be used alongside LTTS’ digital offerings to collect and transfer the vehicle data to the cloud in near real time.
- AnnotAI : For the purpose of developing and testing a self-driving artificial intelligence (AI), a large amount of data is required, along with more engineering and data labeling services. LTTS’ intelligent data annotation platform AnnotAI provides smart labelling to media assets such as text, image, video, and LiDAR, thus empowering global vehicle manufacturers in their drive towards Level 5 autonomy (full driving automation or where the dynamic driving task is eliminated).
- Connected Car : LTTS’ Connected Car technologies offers automotive clients with state-of-the-art driver assistance systems, cloud services and connectivity modules which support in development of V2X platform definition, while implementing secured gateways and avoiding malicious attacks.
- SafeX : The automotive industry faces unique challenges when it comes to developing state-of-the-art software. SafeX DevOps and CI/CD automation allows automotive manufacturers to accelerate their releases while ensuring security and mitigating the risk of failed or recalled software releases.
LTTS’ suite of cutting-edge technologies has resulted in proven benefits for global customers.
A Spokesperson from BMW Group said, “The AnnotAI platform from LTTS, by enabling state-of-the-art image, video, and LiDAR data annotation capabilities on AWS, is driving a robust and integrated validation framework for BMW Group and helping the global leader in luxury vehicles engineer innovative and sustainable vehicles for the future.”
Amit Chadha, CEO and Managing Director, L&T Technology Services said, “Electric, Autonomous and Connected Vehicle (EACV) is the first of our six big bets that are helping global automotive players accelerate their technological development journey towards an autonomous and sustainable future built on the highest considerations of security and safety. By working with AWS, LTTS can help global automotive organizations realize the full potential of its high-performance and scalable technologies built on an agile AWS cloud infrastructure.”
Puneet Chandok, President of Commercial Business, AWS India & South Asia (Amazon Web Services India Pvt. Ltd.) said, “The digital transformation in the automotive industry is accelerating, in many cases thanks to innovative solutions coming from our AWS partners. LTTS’ digital engineering offerings will help our joint customers realize the benefits of moving to the cloud, such as reduced time to market, increased business value and accelerated pace of digital innovation. With the launch of the new Centre of Excellence in India, LTTS will enable customers and original equipment manufacturers (OEM) with a broader range of services and solutions to support their digital transformation journeys.”
Akshat Vaid, Partner at Everest Group said, “For some years now, innovation in mobility has been software and technology centric with themes such as hybrid and electric, autonomous driving, connected experiences, and shared mobility, continuing to be top ER&D spend segments. Cloud and edge computing are naturally at the front and centre in this new era of automotive engineering. Alliances between cloud leaders and engineering service providers will go a long way in helping OEMs in driving best engineering outcomes and in the process creating new possibilities for their end-consumers.”
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 21,600 employees spread across 22 global design centers, 28 global sales offices and 91 innovation labs as of December 31, 2022. For more information, please visit www.ltts.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005905/en/
Contact information
Aniruddha Basu
L&T Technology Services Limited
E: Aniruddha.basu@ltts.com
T: +91-80-67675707
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom